- 商品介绍
- 规格参数
- 包装参数
Biochem/physiol Actions
Lifitegrast, a potent LFA-1 antagonist (IC50 ~2.98 nM), treats Dry Eye Disease by inhibiting T-cell mediated inflammation. It competitively and rapidly binds LFA-1 on T-lymphocytes, blocking interaction with ICAM-1, which inhibits crucial inflammatory processes like T-cell adhesion, migration, activation, and pro-inflammatory cytokine release (e.g., IFN-γ, TNF-α). This action downregulates T-cell activation signaling and inflammatory gene expression, producing targeted anti-inflammatory effects. Administered topically, Lifitegrast exhibits high ocular retention and bioavailability, ensuring localized biological action with minimal systemic exposure.
Disclaimer
Hygroscopic Store with desiccant
| Quality Segment | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| storage condition | desiccated |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | -10 to -25°C |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
-
询价
-
询价
-
¥ 2019.57
-
¥ 1451.54
-
¥ 9207.92
-
询价
-
询价
-
询价
-
询价
-
询价
-
询价
-
¥ 6894.69
-
¥ 9737.84
-
询价
-
¥ 3812.28
-
询价
-
询价
-
询价
-
¥ 2617.87
-
¥ 8137.12
微信小程序
7X24小时在线咨询